Pancreatic Cancer Research

ResearcherCornell UniversityActive in the last 2 years

Jason Stuart Lewis

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-7065-4534; OpenAlex author ID A5068928963, A5132642050; NIH RePORTER profile ID 7614079. Sources: OpenAlex.

Their work

Papers
17 (first author 0, last author 11)
Trials
0
Grants
3
Labs led
1
Collaborators
42
Papers, trials and grants by year

2015: 2 papers · 2016: 1 paper · 2017: none · 2018: none · 2019: 3 papers, 1 grant · 2020: 4 papers · 2021: 2 papers · 2022: 1 paper, 1 grant · 2023: none · 2024: 3 papers · 2025: none · 2026: 1 paper, 1 grant

Papers 17

  1. Trop-2.2-Directed Radioimmunotherapy with 177Lu, 225Ac, and 212Pb in a Pancreatic Cancer Model. Last author DOI 10.1158/1078-0432.ccr-25-2184↗
  2. Multi-parametric atlas of the pre-metastatic liver for prediction of metastatic outcome in early-stage pancreatic cancer. Co-author DOI 10.1038/s41591-024-03075-7↗
  3. 212Pb-Pretargeted Theranostics for Pancreatic Cancer. Last author DOI 10.2967/jnumed.123.266388↗
  4. uPAR Immuno-PET in Pancreatic Cancer, Aging, and Chemotherapy-Induced Senescence. Last author DOI 10.2967/jnumed.124.268278↗
  5. ImmunoPET of Ovarian and Pancreatic Cancer with AR9.6, a Novel MUC16-Targeted Therapeutic Antibody. Co-author DOI 10.1158/1078-0432.ccr-21-1798↗
  6. ERK Inhibition Improves Anti-PD-L1 Immune Checkpoint Blockade in Preclinical Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1158/1535-7163.mct-20-1112↗
  7. Exploiting the MUC5AC Antigen for Noninvasive Identification of Pancreatic Cancer. Co-author DOI 10.2967/jnumed.120.256776↗
  8. Detection of incipient pancreatic cancer with novel tumor-specific antibodies in mouse models Co-author DOI 10.1101/2020.09.10.292193↗
  9. iNOS Regulates the Therapeutic Response of Pancreatic Cancer Cells to Radiotherapy. Last author DOI 10.1158/0008-5472.can-19-2991↗
  10. ImmunoPET Predicts Response to Met-targeted Radioligand Therapy in Models of Pancreatic Cancer Resistant to Met Kinase Inhibitors. Last author DOI 10.7150/thno.37098↗
  11. 89Zr-PET imaging of DNA double-strand breaks for the early monitoring of response following α- and β-particle radioimmunotherapy in a mouse model of pancreatic… Last author DOI 10.7150/thno.44772↗
  12. A PET Imaging Strategy for Interrogating Target Engagement and Oncogene Status in Pancreatic Cancer. Last author DOI 10.1158/1078-0432.ccr-18-1485↗
  13. Leveraging Bioorthogonal Click Chemistry to Improve 225Ac-Radioimmunotherapy of Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1158/1078-0432.ccr-18-1650↗
  14. Retooling a Blood-Based Biomarker: Phase I Assessment of the High-Affinity CA19-9 Antibody HuMab-5B1 for Immuno-PET Imaging of Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-18-3667↗
  15. Pretargeted Immuno-PET of Pancreatic Cancer: Overcoming Circulating Antigen and Internalized Antibody to Reduce Radiation Doses. Last author DOI 10.2967/jnumed.115.163824↗
  16. Site-specifically labeled CA19.9-targeted immunoconjugates for the PET, NIRF, and multimodal PET/NIRF imaging of pancreatic cancer. Last author DOI 10.1073/pnas.1506542112↗
  17. Challenges of Pancreatic Cancer. Co-author DOI 10.1097/ppo.0000000000000109↗

Grants 3

  1. Biostatistics Core P50CA257881↗
  2. Pretargeted Clinical Imaging of CA19.9 in Pancreatic Cancer U01CA221046↗
  3. Histopathologic validation of 89Zr-DFO-HuMab-5B1 PET/CT imaging in CA 19-9 positive pancreatic cancer R01CA222049↗

Closest collaborators

The 25 strongest of 42 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Brian Matthew Zeglis · 4 shared papers, 1 shared grant, 2015–2022 · strength 1.01
  2. Christine A. Iacobuzio–Donahue · 1 shared paper, 1 shared grant, 2020–2026 · strength 0.77
  3. Eileen Mary O'Reilly · 1 shared paper, 1 shared grant, 2019–2026 · strength 0.75
  4. Olca Baştürk · 1 shared grant, 2026 · strength 0.67
  5. Marinela Capanu · 1 shared grant, 2026 · strength 0.67
  6. Vinod P. Balachandran · 1 shared grant, 2026 · strength 0.67
  7. Alice Chia-Chi Wei · 1 shared grant, 2026 · strength 0.67
  8. Edwin Charles Pratt · 2 shared papers, 2024–2026 · strength 0.47
  9. David Bauer · 2 shared papers, 2024–2026 · strength 0.46
  10. Neeta D. Pandit-Taskar · 1 shared paper, 1 shared grant, 2019 · strength 0.36
  11. Wolfgang Weber · 1 shared paper, 1 shared grant, 2019 · strength 0.36
  12. Kelly E. Henry · 3 shared papers, 2019–2021 · strength 0.34
  13. Jacob L. Houghton · 4 shared papers, 2015–2020 · strength 0.31
  14. Michael Ian D'Angelica · 1 shared grant, 2019 · strength 0.28
  15. Sophie Poty · 2 shared papers, 2019–2020 · strength 0.23
  16. Freddy E. Escorcia · 2 shared papers, 2020 · strength 0.22
  17. Patrícia M. R. Pereira · 2 shared papers, 2020 · strength 0.22
  18. Scott W. Lowe · 1 shared paper, 2024 · strength 0.22
  19. James C. Knight · 1 shared paper, 2020 · strength 0.13
  20. Bart T. Cornelissen · 1 shared paper, 2020 · strength 0.13
  21. Nagavarakishore Pillarsetty · 1 shared paper, 2021 · strength 0.13
  22. Sai Kiran Sharma · 1 shared paper, 2022 · strength 0.13
  23. Michael Anthony Hollingsworth · 1 shared paper, 2022 · strength 0.13
  24. Prakash Radhakrishnan · 1 shared paper, 2022 · strength 0.13
  25. Jan Grimm · 1 shared paper, 2021 · strength 0.11

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.